U.S. clears AstraZeneca over heart drug trial
LONDON Aug 19 (Reuters) - AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.
The decision last October by the U.S. Department of Justice to investigate the study cast doubts over the future of the medicine, which AstraZeneca argues is a potential $3.5 billion-a-year seller but which has so far registered only modest sales.
- Obama makes rare campaign trail appearance, people leave early
- Obama makes rare campaign trail appearance, some leave early
- Turkey to let Iraqi Kurds reinforce Kobani as U.S. drops arms to defenders |
- Nigeria declared Ebola-free, holds lessons for others
- Two arrested in death of Saudi student in California: report